US2009239952A1PendingUtilityA1
Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
Est. expiryApr 15, 2025(expired)· nominal 20-yr term from priority
A61P 43/00A61P 35/00A61P 1/04A61K 31/122A61P 17/00A61K 31/53A61P 17/04A61P 17/02A61K 39/395
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides methods and compositions tor treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (BGKR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.
Claims
exact text as granted — not AI-modified1 . A method for treating a skin rash secondary to an anti-epidermal growth factor receptor (EGFR) therapy in a subject receiving said therapy, the method comprising applying a vitamin K analog to the skin rash in an amount effective to treat the skin rash.
2 - 71 . (canceled)Join the waitlist — get patent alerts
Track US2009239952A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.